Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTP4A3 | O75365 | 1/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 4/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286663 | 0.84 | TRPV4 (0.52) | TRPV4ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL16956451 | 0.81 | ALDH1A1 (0.43) | TRPV4ALDH1A1TP53TDP1TRPA1 | |
| SCHEMBL4817679 | 0.81 | PTP4A3 (0.43) | PTP4A3TRPV4ARGRM4CNR2 | |
| SCHEMBL4758341 | 0.80 | ALDH1A1 (0.39) | PTP4A3ALDH1A1TP53TDP1TRPA1 | |
| SCHEMBL16957506 | 0.80 | PTP4A3 (0.46) | PTP4A3TRPV4ARGRM4CNR2 | |
| SCHEMBL48778 | 0.80 | PTP4A3 (0.49) | PTP4A3TRPV4ALDH1A1ARGRM4 | |
| SCHEMBL31290788 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TP53TDP1TRPA1 | |
| SCHEMBL22418044 | 0.77 | PTP4A3 (0.43) | PTP4A3TRPV4ALDH1A1ARCNR2 | |
| SCHEMBL16959333 | 0.76 | ALDH1A1 (0.39) | ALDH1A1GRM4TP53TDP1TRPA1 | |
| SCHEMBL13285691 | 0.76 | TRPA1 (0.47) | ALDH1A1TP53TDP1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3997096-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20220242876-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3997096-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022086840-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-114096545-A | Novel heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2022-02-25 | — | — | CN | disclosed |
| WO-2021005034-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-01-14 | — | — | WO | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-1966152-A2 | GLUCOKINASE ACTIVATORS | Takeda Pharmaceutical Company Limited (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | disclosed |
| WO-2007075847-A2 | GLUCOKINASE ACTIVATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075847-A2 | GLUCOKINASE ACTIVATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242876-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP1A2 | PTP4A3 4533/4885TRPV4 3413/4885ALDH1A1 270/4885 |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | PTP4A3 4048/4885TRPV4 4033/4885ALDH1A1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.